Twelve weeks of treatment with the direct-acting antiviral (DAA) all-oral combination of ledipasvir plus sofosbuvir for genotype 1 hepatitis C virus (HCV) infection shows “real-world” effectiveness, according to a new study.
Early data regarding the “real-world” experience with novel DAAs are encouraging, with sustained virologic response (SVR) rates of 93% to 96% after 8 to12 weeks of ledpasivir-sofosbuvir. These results mirror the SVR rates observed in clinical trials with the combination. However, until now, data were lacking on “real-world” results with treatment-experienced patients.
“Our study linked data from healthcare clinics to specialty pharmacies dispensing medication. This is highly characteristic of the cohort of patients seen in the community and in academic centers, with both women and men of different races. This diverse sample of patients reflects healthcare treatment, including those who had previously been treated for HCV,” Elliott Tapper, MD, assistant professor of medicine at University of Michigan, told Medical Economics.
The researchers published their results in the January 2017 Journal of Viral Hepatitis.
Tapper and colleagues conducted a retrospective cohort study of 1597 patients, age 60 years on average, with chronic genotype 1 HCV who were treated for 12 weeks with a regimen of ledpasivir-sofosbuvir without ribavirin (1521 patients) or with ribavirin (76 patients).